TMX Newsfile·2026-01-22 23:10Core Viewpoint - A class action lawsuit has been filed against Vistagen Therapeutics, Inc. for allegedly providing misleading information regarding its drug fasedienol during the Class Period from April 1, 2024, to December 16, 2025 [1][5][6] Group 1: Lawsuit Details - The lawsuit claims that Vistagen made positive assertions about the success of fasedienol based on prior clinical trial results, while concealing material adverse facts about the Phase 3 PALISADE-3 trial [5][6] - Investors who purchased Vistagen common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2][3] Group 2: Legal Representation - The Rosen Law Firm, which is leading the class action, has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 [4] - Investors are encouraged to select qualified legal counsel with a proven history in leadership roles within class action lawsuits [4] Group 3: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][7] - A lead plaintiff must be appointed by March 16, 2026, to represent the interests of other class members [1][3]